Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 46Lung Neoplasms 19Melanoma 18Neoplasm Metastasis 16Carcinoma, Hepatocellular 15Neoplasms 13Esophageal Neoplasms 12Squamous Cell Carcinoma of Head and Neck 10Colorectal Neoplasms 9Breast Neoplasms 9Head and Neck Neoplasms 8Stomach Neoplasms 6Rectal Neoplasms 6Esophageal Squamous Cell Carcinoma 6Carcinoma, Renal Cell 6Brain Neoplasms 6Small Cell Lung Carcinoma 5Recurrence 5Pancreatic Neoplasms 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 4Sarcoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Multiple Myeloma 4Liver Neoplasms 4Glioblastoma 4Cholangiocarcinoma 4Prostatic Neoplasms 3Nasopharyngeal Carcinoma 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3

Interventions

trifluridine tipiracil drug combination 1camrelizumab 1anlotinib 1Radiotherapy 1Induction Chemotherapy 1Immunotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
ESCC × Immunotherapy × Clear all
NCT07015489 2025-06-11

Concurrent Radiotherapy Following Induction Chemoimmunotherapy for Locally Advanced Esophageal Cancer

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Completed
44 enrolled

ESCC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡